Last reviewed · How we verify
Chloroquine- P. vivax
At a glance
| Generic name | Chloroquine- P. vivax |
|---|---|
| Sponsor | Centers for Disease Control and Prevention |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Serological Testing and Treatment for Plasmodium Vivax Malaria: a Trial in Ethiopia and Madagascar (PHASE3)
- This is a Clinical Study to Assess Whether the Combination of SJ733 and Tafenoquine Will be a Safe and Rapidly Acting Anti-malarial for the Radical Cure of P. Vivax Malaria (PHASE2)
- Vivax Elimination With Tafenoquine (VET) Study (PHASE4)
- An Interventional Study to Compare the Efficacy and Safety of Tafenoquine (TQ) and Primaquine (PQ) When Either Are Taken Together With Chloroquine (CQ) for the Treatment of P. Vivax Malaria in Indian Participants Aged 2 Years and Older (PHASE3)
- Radical CUREfor MAlaria Among Highly Mobile and Hard-to-reach Populations in the Guyanese Shield (NA)
- ACT vs CQ With Tafenoquine for P. Vivax Mono-infection (PHASE4)
- Short Course Radical Cure of P. Vivax Malaria in Nepal (PHASE4)
- A Study to Assess Safety of Current Standard Malaria Treatment and an Assessment of G6PD Status in South-east Bangladesh (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Chloroquine- P. vivax CI brief — competitive landscape report
- Chloroquine- P. vivax updates RSS · CI watch RSS
- Centers for Disease Control and Prevention portfolio CI